Dual antiplatelet therapy
ApprovedSmall molecule
Dual antiplatelet therapy is one of 166 small molecule programs targeting Stroke. It is currently in Approved.
6
Indications
13
Total Trials
8
Active Trials
165
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
461 competitors in Stroke
#DrugCompanyPhaseTrials
1Dual antiplatelet therapy
SSeoul St. Mary's Hospital
Approved
Zometa
PfizerPreclinical
Folvite
Eli LillyPreclinical
Proamatine
TakedaPreclinical
Botox
RRevance Therapeutics, Inc.
Preclinical
Zantac 150
CChattem
Preclinical
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Direct Anticoagulant
BayerPreclinical
Inderal
Mylan Pharmaceuticals IncPreclinical
Carbidopa-Levodopa
Neurocrine BiosciencesPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Antithrombotic1 trial
Rivaroxaban1 trial
Rivaroxaban for Slow Coronary Flow After PCI in STEMI
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT07195812·60 enrolled
8 more indications
Coronary Artery Bypass1 trial
Aneurysm1 trial
Antiplatelet Therapy1 trial
Acute Myocardial Infarction1 trial
Stroke, Acute1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dual antiplatelet therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- SSeoul St. Mary's Hospital